Edition:
United States

NeuroVive Pharmaceutical AB (NVP.ST)

NVP.ST on Stockholm Stock Exchange

4.55SEK
8:02am EDT
Change (% chg)

0.15kr (+3.41%)
Prev Close
4.40kr
Open
4.42kr
Day's High
4.60kr
Day's Low
4.42kr
Volume
19,702
Avg. Vol
411,598
52-wk High
7.96kr
52-wk Low
2.90kr

Latest Key Developments (Source: Significant Developments)

Neurovive Q4 pretax loss doubles yr/yr
Tuesday, 21 Feb 2017 02:30am EST 

Neurovive Pharmaceutical AB :Q4 loss before tax was SEK 14.6 million (7.4).  Full Article

Neurovive Q2 loss narrows
Thursday, 18 Aug 2016 02:30am EDT 

Neurovive Pharmaceutical : Q2 loss before tax was SEK 12,059,000 (15,216,000) .Q2 net revenues were SEK 0 (2,502,000).  Full Article

NeuroVive says completes 10 pct acquisition of Isomerase Therapeutics
Monday, 15 Aug 2016 07:30am EDT 

NeuroVive Pharmaceutical AB : NeuroVive completes 10 percent acquisition of Isomerase Therapeutics .Says now completed acquisition includes approximately 5 percent further of shares in Isomerase through a 550 000 GBP cash payment.  Full Article

Neurovive Q1 loss before tax narrows to SEK 11 mln
Tuesday, 31 May 2016 02:36am EDT 

Neurovive Pharmaceutical AB : Q1 net revenues were SEK 0 (0) and other operating income was SEK 46,000 (49,000) . Q1 loss before tax was SEK 10,916,000 (14,271,000) For the original story click here: http://mb.cision.com/Main/6574/2019911/522487.pdf Further company coverage: [NVP.ST] (Stockholm Newsroom) ((stockholm.newsroom@thomsonreuters.com; +46 (0)8-700 10 10;)).  Full Article

Neurovive Pharmaceutical AB says insiders intend to subscribe for at least 5.4 million swedish crowns in rights issue
Tuesday, 26 Apr 2016 06:30am EDT 

Neurovive Pharmaceutical AB:Says insiders and employees intend to subscribe for a minimum of 5.4 million swedish crowns.Says that board members, other insiders and employees intend to subscribe for a minimum of 129 000 units, equivalent to at least 5.4 million swedish crowns, in the company's preferential rights issue with the subscription period between 18 April and 2 May.  Full Article

Neurovive Pharmaceutical AB announces Erik Kinnman new CEO
Tuesday, 23 Feb 2016 02:30am EST 

Neurovive Pharmaceutical AB:Says has selected Erik Kinnman as NeuroVive's Chief Executive Officer.Kinnman will assume the new role on March 14.  Full Article

Neurovive buys stake in Isomerase Therapeutics, issues new shares
Thursday, 14 Jan 2016 02:30am EST 

Neurovive Pharmaceutical AB:Buys stake in Isomerase Therapeutics.Says ‍acquires about 5 pct shares in Isomerase with payment in own shares​.Says ‍later this year Neurovive will acquire about 5 pct further of shares in Isomerase as a cash payment of 550,000 GBP.Says will issue 738,533 new shares, giving a purchase price for the first step amounting to about 6.8 million was based on the average closing price of NeuroVive shares on Nasdaq Stockholm from Dec. 23-Jan. 12.Says the Non-Cash Consideration entails a dilution of about 2.4 pct​.  Full Article

Neurovive says safety committee endorses continuation of CiPRICS study
Thursday, 19 Nov 2015 02:30am EST 

Neurovive Pharmaceutical AB:Says reports favorable safety evaluation in phase II acute kidney injury study.Says the independent safety committee has endorsed the continuation of the on-going Phase II CiPRICS (Ciclosporin to Protect Renal function In Cardiac Surgery) study following the enrollment of the first 50 patients in the study.  Full Article

Neurovive Pharmaceutical says OCB-030 preclinical program has been discontinued by Arbutus
Wednesday, 28 Oct 2015 08:15am EDT 

Neurovive Pharmaceutical AB:Neurovive says aims to find path forward in antiviral development following discontinuation of OCB-030 preclinical program by Arbutus.Says Arbutus Biopharma has decided to discontinue development of OCB-030 (NVP018) so company can focus its resources on other agents that directly target HBV.Says "believes that the compound still has future potential based on the extensive, independent evidence that supports its application in this area".  Full Article

Neurovive Pharmaceutical says Jan Nilsson new interim CEO
Tuesday, 1 Sep 2015 07:55am EDT 

Neurovive Pharmaceutical AB:Says Jan Nilsson new interim CEO.CEO Mikael Bronnegard to leave company.  Full Article

More From Around the Web

BRIEF-NeuroVive enters research agreements in NASH and hepatocellular carcinoma

* Says appoints recognized scientific advisors and enters research agreements in NASH and hepatocellular carcinoma Source text for Eikon: Further company coverage: